Chesapeake Capital Corp IL Buys 1,347 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Chesapeake Capital Corp IL lifted its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 27.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,176 shares of the company’s stock after buying an additional 1,347 shares during the period. Chesapeake Capital Corp IL’s holdings in Twist Bioscience were worth $287,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Victory Capital Management Inc. grew its position in shares of Twist Bioscience by 7.7% in the 3rd quarter. Victory Capital Management Inc. now owns 331,809 shares of the company’s stock worth $14,991,000 after buying an additional 23,638 shares during the last quarter. Aigen Investment Management LP increased its position in Twist Bioscience by 84.0% during the third quarter. Aigen Investment Management LP now owns 9,037 shares of the company’s stock valued at $408,000 after acquiring an additional 4,125 shares during the last quarter. Los Angeles Capital Management LLC increased its position in Twist Bioscience by 18.3% during the third quarter. Los Angeles Capital Management LLC now owns 12,192 shares of the company’s stock valued at $551,000 after acquiring an additional 1,888 shares during the last quarter. Privium Fund Management B.V. grew its holdings in Twist Bioscience by 53.4% during the third quarter. Privium Fund Management B.V. now owns 6,950 shares of the company’s stock valued at $314,000 after purchasing an additional 2,420 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in Twist Bioscience by 67.5% during the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock valued at $9,301,000 after purchasing an additional 82,953 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on TWST. Evercore ISI upped their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Leerink Partners increased their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Robert W. Baird upped their price objective on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. Barclays reduced their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Finally, JPMorgan Chase & Co. increased their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.22.

Twist Bioscience Trading Down 5.3 %

Shares of NASDAQ TWST opened at $36.89 on Monday. The stock has a market capitalization of $2.16 billion, a PE ratio of -9.66 and a beta of 1.78. The stock’s fifty day simple moving average is $43.90 and its two-hundred day simple moving average is $46.11. Twist Bioscience Co. has a 12-month low of $18.80 and a 12-month high of $60.90.

Insider Buying and Selling at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,730 shares of the firm’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $46.94, for a total value of $81,206.20. Following the completion of the sale, the chief executive officer now owns 495,523 shares of the company’s stock, valued at $23,259,849.62. This trade represents a 0.35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Patrick John Finn sold 6,865 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total value of $296,636.65. Following the completion of the sale, the chief operating officer now directly owns 161,744 shares of the company’s stock, valued at $6,988,958.24. The trade was a 4.07 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 98,118 shares of company stock valued at $4,391,151. 3.92% of the stock is currently owned by corporate insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.